CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease

Annals of Clinical Biochemistry - Tập 46 Số 6 - Trang 477-483 - 2009
Sandra D. Mulder1,2, Johannes A. Heijst1,2, Cees Mulder1,2, Frans Martens2, C. Erik Hack2, Philip Scheltens1,3, Marinus A. Blankenstein1,2, Robert Veerhuis1,2,4
1Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
2Department of Clinical Chemistry
3Department of Neurology
4Department of Psychiatry

Tóm tắt

Background Prostate-specific antigen (PSA) is a serine protease that in serum, is predominantly found complexed to the serine protease inhibitor alpha1-antichymotrypsin (ACT). ACT co-localizes with amyloid plaques in Alzheimer's disease (AD) brain and both PSA and ACT are detectable in cerebrospinal fluid (CSF). Therefore, we aimed to determine whether PSA is produced in the brain and whether PSA and PSA–ACT complex levels in CSF can be used as a biomarker for AD. Methods Levels of ACT and PSA–ACT were determined by sandwich enzyme-linked immunosorbent assay in CSF and serum samples of AD ( n = 16), frontotemporal lobe dementia (FTLD) ( n = 19), mild cognitively impaired (MCI) patients ( n = 19) and controls ( n = 12). Total PSA was determined in a non-competitive immunoassay. Reverse transcriptase–polymerase chain reaction (RT–PCR) for PSA was performed on postmortem hippocampus and temporal cortex specimens from control and AD cases. Results PSA is expressed in the brain, as detected by RT–PCR. PSA and PSA–ACT complexes were detectable in CSF of almost all male and only very few female subjects. The levels of PSA and PSA–ACT complexes in CSF did not differ between AD, FTLD, MCI and control groups. PSA CSF/serum quotients highly correlated with albumin CSF/serum quotients. Furthermore, the hydrodynamic radius of PSA was found to be 3 nm and the theoretical PSA quotient, derived from the Felgenhauer plot, corresponded well with the measured PSA quotient. Conclusions PSA is locally produced in the human brain; however, brain PSA hardly contributes to the CSF levels of PSA. PSA and PSA–ACT levels in CSF are not suitable as a biomarker for AD.

Từ khóa


Tài liệu tham khảo

10.1016/0197-4580(90)90045-2

Pasternack JM, 1989, Am J Pathol, 135, 827

10.1523/JNEUROSCI.21-05-01444.2001

10.1016/S0002-9440(10)64839-0

10.1111/j.1749-6632.1992.tb27485.x

10.1002/ana.10414

10.1097/00002093-199509020-00009

10.1002/ana.410280414

10.1212/01.wnl.0000271077.82508.a0

10.1212/01.WNL.0000158281.08946.68

10.1016/S0094-0143(05)70373-6

10.1373/clinchem.2007.088104

Stone JG, 2009, Int J Clin Exp Pathol, 2, 267

10.1159/000283070

10.1093/clinchem/43.5.855

10.1177/172460088600100210

Stenman UH, 1991, Cancer Res, 51, 222

10.1016/S0090-4295(00)00519-7

10.1016/S0197-4580(00)00124-X

10.1212/01.wnl.0000271375.37131.04

10.1016/S0009-8981(01)00573-3

10.1159/000116919

SchuitemakerA, DikMG, VeerhuisR, Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 2008;Epub ahead of print. DOI: 10.1016/j.neurobiolaging.2008.01.014

10.1007/BF00294446

10.1007/BF00308809

10.1021/bi0607047

Felgenhauer K, 1999, Labordiagnostik neurologischer Erkrankungen: Liquoranalytik und – zytologie, Diagnose – und Prozeßmarker

10.1007/BF01466734

10.1016/S0378-1119(00)00382-6

10.1097/PAS.0b013e3180536678

10.1097/00001756-200108280-00031

10.1007/s004150050433

de Vries HE, 1997, Pharmacol Rev, 49, 143

10.1016/S0022-5347(01)67622-5

10.1210/jcem.80.5.7538144

10.1016/0197-4580(91)90042-I

10.1016/0197-4580(94)90026-4

Reiber H, 2003, Restor Neurol Neurosci, 21, 79

10.1111/j.1468-1331.2007.01968.x

10.1038/bjc.1998.397

10.1093/clinchem/41.10.1480

10.1093/clinchem/44.6.1216

10.1093/clinchem/37.9.1618

Thông tin
Thông tin xuất bản

Annals of Clinical Biochemistry

Tập 46 Số 6

477-483

Thông tin tác giả